232 related articles for article (PubMed ID: 29170874)
1. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
[TBL] [Abstract][Full Text] [Related]
2. Single dose NTBC-treatment of hereditary tyrosinemia type I.
Schlune A; Thimm E; Herebian D; Spiekerkoetter U
J Inherit Metab Dis; 2012 Sep; 35(5):831-6. PubMed ID: 22307209
[TBL] [Abstract][Full Text] [Related]
3. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
[TBL] [Abstract][Full Text] [Related]
4. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
5. Laboratory monitoring of patients with hereditary tyrosinemia type I.
Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients.
van Ginkel WG; van Reemst HE; Kienstra NS; Daly A; Rodenburg IL; MacDonald A; Burgerhof JGM; de Blaauw P; van de Krogt J; Santra S; Heiner-Fokkema MR; van Spronsen FJ
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752110
[TBL] [Abstract][Full Text] [Related]
7. Tyrosinemia type I: Case series with response to treatment to NTBC.
Shah I; Shah F
Indian J Gastroenterol; 2016 May; 35(3):229-31. PubMed ID: 27109516
[TBL] [Abstract][Full Text] [Related]
8. Simple and fast quantification of nitisone (NTBC) using liquid chromatography-tandem mass spectrometry method in plasma of tyrosinemia type 1 patients.
Davit-Spraul A; Romdhane H; Poggi-Bach J
J Chromatogr Sci; 2012 May; 50(5):446-9. PubMed ID: 22511487
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
Hall MG; Wilks MF; Provan WM; Eksborg S; Lumholtz B
Br J Clin Pharmacol; 2001 Aug; 52(2):169-77. PubMed ID: 11488774
[TBL] [Abstract][Full Text] [Related]
10. Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis.
Cansever MS; Aktuğlu-Zeybek AC; Erim FB
Talanta; 2010 Mar; 80(5):1846-8. PubMed ID: 20152421
[TBL] [Abstract][Full Text] [Related]
11. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?
El-Karaksy H; Rashed M; El-Sayed R; El-Raziky M; El-Koofy N; El-Hawary M; Al-Dirbashi O
Eur J Pediatr; 2010 Jun; 169(6):689-93. PubMed ID: 19882170
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients.
Herebian D; Spiekerkötter U; Lamshöft M; Thimm E; Laryea M; Mayatepek E
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(14-15):1453-9. PubMed ID: 19345648
[TBL] [Abstract][Full Text] [Related]
13. Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography-tandem mass spectrometry. Study of the stability of the samples at different temperatures.
Prieto JA; Andrade F; Lage S; Aldámiz-Echevarría L
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(11-12):671-6. PubMed ID: 21377430
[TBL] [Abstract][Full Text] [Related]
14. Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).
Sander J; Janzen N; Terhardt M; Sander S; Gökcay G; Demirkol M; Ozer I; Peter M; Das AM
Clin Chim Acta; 2011 Jan; 412(1-2):134-8. PubMed ID: 20883679
[TBL] [Abstract][Full Text] [Related]
15. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1.
Sundberg J; Wibrand F; Lund AM; Christensen M
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():259-266. PubMed ID: 29195145
[TBL] [Abstract][Full Text] [Related]
17. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients.
van Vliet K; van Ginkel WG; Jahja R; Daly A; MacDonald A; De Laet C; Vara R; Rahman Y; Cassiman D; Eyskens F; Timmer C; Mumford N; Bierau J; van Hasselt PM; Gissen P; Goyens PJ; McKiernan PJ; Wilcox G; Morris AAM; Jameson EA; Huijbregts SCJ; van Spronsen FJ
Orphanet J Rare Dis; 2019 Dec; 14(1):285. PubMed ID: 31801588
[TBL] [Abstract][Full Text] [Related]
18. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
[TBL] [Abstract][Full Text] [Related]
19. Treatment adherence in tyrosinemia type 1 patients.
González-Lamuño D; Sánchez-Pintos P; Andrade F; Couce ML; Aldámiz-Echevarría L
Orphanet J Rare Dis; 2021 Jun; 16(1):256. PubMed ID: 34082789
[TBL] [Abstract][Full Text] [Related]
20. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat.
Lock EA; Gaskin P; Ellis MK; Provan WM; Robinson M; Smith LL; Prisbylla MP; Mutter LC
Toxicol Appl Pharmacol; 1996 Dec; 141(2):439-47. PubMed ID: 8975769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
